Healthcare Industry News: Janssen
News Release - July 6, 2006
Eisai Inc. Announces Appointment of Vice President of Business DevelopmentTEANECK, NJ--(Healthcare Sales & Marketing Network)--Jul 6, 2006 -- Eisai Inc. today announces the immediate appointment of Alex Scott as Vice President of Business Development. In his new role, Mr. Scott will oversee all business development activities, targeting opportunities in Eisai's three areas of therapeutic focus -- neurology, gastrointestinal disorders and oncology/critical care.
Mr. Scott joined Eisai in 1992 as Manager of Corporate Affairs at Eisai Corporation of North America. Before assuming his current role, he held several positions of increasing responsibility in Corporate Affairs, Planning and Business Development within Eisai U.S. operations.
Mr. Scott has been instrumental in crafting Eisai's globalization strategy, establishing commercial infrastructure, and negotiating global alliances with, for example, Pfizer and Janssen for Aricept® (donepezil hydrochloride tablets) and Aciphex®/Pariet® (rabeprazole sodium) tablets, respectively. Both Aricept® and Aciphex®/Pariet® were discovered and developed by Eisai. In addition, he has played a key role in the successful conclusion of deals with Pfizer for an anti-coagulant, Dainippon for AS-3201, Elan for Zonegran® (zonisamide) capsules and Novartis for rufinamide.
"Eisai is committed to pursuing innovative products that fulfill our human health care (hhc) mission to satisfy unmet medical needs and increase benefits to patients and their families," said Lonnel Coats, President & COO. "With his strong history of success, we are confident Mr. Scott will continue to contribute to Eisai's mission, vision and growth in his new role."
About Eisai Inc.
Eisai Inc. is a U.S. pharmaceutical subsidiary of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products in more than 30 countries. Eisai focuses its efforts in three therapeutic areas: neurology, gastrointestinal disorders and oncology/critical care. Established in 1995, Eisai Inc. began marketing its first product in the United States in 1997 and has rapidly grown to become an integrated pharmaceutical business with sales of approximately $2.2 billion in fiscal year 2005 (year ended March 31, 2006).
Eisai Inc. employs more than 1,300 people at its headquarters in Teaneck, NJ, at its state-of-the-art pharmaceutical production and formulation research and development facility in Research Triangle Park, NC, and in the field. Between 1998 and 2005, Eisai Inc. moved up rapidly in the rankings (based on retail sales) of U.S. pharmaceutical companies from No. 44 to No. 19. For more information about Eisai, please visit www.eisai.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.